Zydus Lifesciences Q2 FY27 Financial and Operational Performance Summary
Zydus Lifesciences Ltd 路 Investor Presentation 路 04 Nov 2026, 6:07 pm
Zydus Lifesciences Q2 FY27 Financial and Operational Performance Summary Zydus Lifesciences reported a 29.2% YoY increase in consolidated revenue from operations to Rs. 79,096 mn for Q2 FY27, driven by 20.8% YoY growth in North America formulations (Rs. 33,145 mn) and 18.3% YoY growth in India formulations (Rs. 18,844 mn). EBITDA declined 6.0% YoY to Rs. 18,945 mn with margins contracting 890 bps to 24.0%. Reported net profit fell 26.6% YoY to Rs. 9,255 mn, impacted by higher depreciation and operating expenses. Organic capex stood at Rs. 4,655 mn, while net debt closed at Rs. 51,998 mn.
Original exchange filing (PDF)
More announcements from Zydus Lifesciences Ltd
- Press Release 路 14 Nov 2026
- Completion of transaction 路 12 Nov 2026
- Transcript of the post results earnings call held on November 4, 2026. 路 07 Nov 2026
- Press Release 路 07 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India 路 06 Nov 2026
- Investor Conference 路 06 Nov 2026
- Audio recording of the Company's Investor Call 路 05 Nov 2026
- Press Release 路 04 Nov 2026
